37b95452-c6ab-48f9-abd4-521b33596657
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 49.8316221765914
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.470
- MYC_TARGETS_V2+0.390
- UNFOLDED_PROTEIN_RESPONSE+0.350
- MYC_TARGETS_V1+0.260
- DNA_REPAIR+0.240
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.230
- P53_PATHWAY+0.220
- CHOLESTEROL_HOMEOSTASIS+0.200
- PEROXISOME+0.170
- FATTY_ACID_METABOLISM+0.100
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.600
- ANGIOGENESIS-0.540
- INFLAMMATORY_RESPONSE-0.420
- UV_RESPONSE_DN-0.420
- COMPLEMENT-0.370
- KRAS_SIGNALING_UP-0.370
- COAGULATION-0.350
- INTERFERON_GAMMA_RESPONSE-0.340
- TNFA_SIGNALING_VIA_NFKB-0.310
- ALLOGRAFT_REJECTION-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013506 | — | cohortA2 | 0.900 |
| 2 | ERR2278860 | — | — | 0.885 |
| 3 | R32 | — | — | 0.876 |
| 4 | ERR2278847 | — | — | 0.873 |
| 5 | TCGA-CQ-6225-01A-11R-1915-07 | — | — | 0.871 |
| 6 | MNG265 | — | — | 0.867 |
| 7 | TCGA-5T-A9QA-01A-11R-A41B-07 | — | B | 0.860 |
| 8 | SRR12475110 | — | — | 0.856 |
| 9 | SRR26320073 | — | — | 0.841 |
| 10 | SRR10900578 | — | — | 0.835 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.470 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.390 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.350 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.260 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.230 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.220 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| PEROXISOME | 0.170 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.090 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.060 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.040 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.020 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.020 | Inavolisib | — uncovered |